SRXH
SRX Global Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 17 SRx Health Solutions provided an update on its proposed merger with…
- Jun 18 ▼ SRx Health Solutions closed its acquisition of EMJ Crypto Technologi…
- Jun 18 SRx Health Solutions completed its acquisition of EMJ Crypto Technol…
- Jul 16 ▲ SRX Global announced it has regained full compliance with NYSE Ameri…
- Jul 16 ▲ SRX Global (SRXH) received written notification from NYSE Regulation…
- Jul 16 Activist stake: SRX Global Regains Full Compliance with NYSE American List…
- Aug 4 ▲ SRX Global Inc. (SRXH) announced it has acquired a stake in Vistagen…
- Aug 31 Contract: SRX Global Acquires Senior Secured Debt in CERo Therapeuti…
- Sep 24 Activist stake: SRX Global Provides Shareholders with Update on Liquidatio…
- Oct 7 SRX Global Inc. (SRXH) entered into a Stock Purchase Agreement to ac…
- Oct 30 ▲ Buyback: SRX Global Provides Update on Balance Sheet and Share Buyb…
- Oct 30 ▲ Short interest falls 47.6% to 998.5K
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q2 2026: 4 added (0 new), 0 trimmed or exited.
- Short sellersCOVERING
Short interest −47.6% to 998.5K shares. 2.3 days to cover, ≈4.9% of shares.
- TrendDOWNTREND
37% below its 50-day average. New closing low $0.8000 on Nov 20.
- SocialQUIET
Crowd 60° (warm) this week from 1 mention: 1 bullish, 0 bearish. No setup is alerting.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | $634.4K |
| JANE STREET GROUP, LLC | DOUBLED | $307.5K |
| UBS Group AG | DOUBLED | $47.7K |
| CITIGROUP INC | DOUBLED | $47.2K |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | $31.9K |
| SCOTIA CAPITAL INC. | DOUBLED | $13.9K |
| UBS Group AG | ADD | $11.1K |
| VANGUARD GROUP INC | ADD | $64.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Cunningham Kent Douglas Chief Executive Officer Mar 16, 2026 | AWARD | $50.4K |
Cunningham Kent Douglas Chief Executive Officer Mar 16, 2026 | AWARD | $78.8K |
Cunningham Kent Douglas Chief Executive Officer Dec 3, 2025 | AWARD | $78.0K |
Conway Simon Alexander Malcolm Director Dec 3, 2025 | AWARD | $245.7K |
Cunningham Kent Douglas Chief Executive Officer Sep 26, 2025 | AWARD | $14.7K |
Cunningham Kent Douglas Chief Executive Officer Aug 25, 2025 | AWARD | $93.4K |
Conway Simon Alexander Malcolm Director Aug 25, 2025 | AWARD | $61.7K |
Cunningham Kent Douglas Chief Executive Officer Apr 25, 2025 | AWARD | $135.0K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | None | None | No data | $0.00 |
| Next Q | None | None | No data | $0.00 |
| Current FY | None | None | No data | $0.00 |
| Next FY | None | None | No data | $0.00 |
Short side
FINRA· Oct 30, 2026| Jul 9, 2026 | Volatility Pause | Resumed |
| Jul 9, 2026 | Resumption Scheduled | Resumed |
| Jul 8, 2026 | Resumption Scheduled | Resumed |
| Jul 6, 2026 | Volatility Pause | Resumed |
| Jul 6, 2026 | Volatility Pause | Resumed |
SecBot reports
16 filings · 14 press releases · 1 bullish · 3 bearish · 3 mixed · 9 neutral- NEUTRAL PRESS RELEASENov 20, 2026
SRX Global issued a press release commenting on Pfizer's $330M upfront licensing deal with Starna…
Monitor the pending acquisition of CERo Therapeutics for closing conditions and any further clinical data from the CERTAIN-T trial. The activist stake filed on the same day may increase pressure on…
- NEUTRAL SC 13DNov 20, 2026
Kevin Egan and Lee Kiewiet filed a Schedule 13D disclosing a group that collectively owns 9.9% of…
Watch for the group's next steps: a formal board nomination notice, a 13D amendment with specific proposals, or engagement with potential acquirers. The company's small market cap and declining…
- NEUTRAL PRESS RELEASEOct 30, 2026
SRX Global provided a balance sheet update and share buyback program status. The company holds…
Monitor the December 2026 fiscal year-end report for actual share repurchase details and full financial results. The cash position and buyback authorization suggest management views the stock as…
- MIXED 8-KOct 7, 2026
SRX Global Inc. (SRXH) entered into a Stock Purchase Agreement to acquire CERo Therapeutics, Inc…
Watch the 30-day go-shop period ending ~Nov 5, 2026 for any superior proposals. The Series A preferred holder conversion/waiver condition and preferred stock acquisition by SRX are key gating items…
All SRXH filing & press-release reports (30)
- PRESS-RELEASE reportNov 20, 2026
- SC 13D reportNov 20, 2026
- PRESS-RELEASE reportOct 30, 2026
- 8-K reportOct 7, 2026
- 8-K reportOct 6, 2026
- PRESS-RELEASE reportSep 24, 2026
- 8-K reportSep 9, 2026
- 8-K reportSep 2, 2026
- 8-K reportAug 28, 2026
- 8-K reportAug 19, 2026
- PRESS-RELEASE reportAug 4, 2026
- PRESS-RELEASE reportAug 3, 2026
- PRESS-RELEASE reportJul 30, 2026
- 8-K reportJul 28, 2026
- 8-K reportJul 16, 2026
- PRESS-RELEASE reportJul 16, 2026
- 8-K reportJul 15, 2026
- 8-K reportJun 26, 2026
- 8-K reportJun 18, 2026
- PRESS-RELEASE reportJun 18, 2026
- PRESS-RELEASE reportJun 8, 2026
- PRESS-RELEASE reportMay 29, 2026
- EFFECT reportMay 8, 2026
- 8-K reportApr 22, 2026
- 8-K reportApr 17, 2026
- PRESS-RELEASE reportApr 16, 2026
- PRESS-RELEASE reportApr 7, 2026
- PRESS-RELEASE reportMar 25, 2026
- PRESS-RELEASE reportMar 18, 2026
- 8-K reportMar 3, 2026